Cilastatin sodium is a competitive, reversible and specific inhibitor of dehydropeptidase-I, the renal enzyme which metabolizes and inactivates imipenem. It is devoid of intrinsic antibacterial activity and does not affect the antibacterial activity of imipenem.
Imipenem and Cilastatin for Injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms.
When not to Use
Imipenem and Cilastatin for Injection is contraindicated in patients who have shown hypersensitivity to any component of this product.
CNS adverse experiences such as confusional states, myoclonic activity, and seizures have been reported during treatment with Imipenem and Cilastatin for Injection, especially when recommended dosages were exceeded.
Patients should be counseled to inform their physician if they are taking valproic acid or divalproex sodium.
Cilastatin for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Patients with creatinine clearances of =5 mL/min/1.73 m2 should not receive Imipenem and Cilastatin for Injection unless hemodialysis is instituted within 48 hours.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.